<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<References xsi:schemaLocation="http://www.iedb.org/schema/CurationSchema http://beta.iedb.org/schema/Curation.xsd" xmlns="http://www.iedb.org/schema/CurationSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <Reference>
        <ReferenceId>1282</ReferenceId>
        <DateLastUpdated>2020-09-10-07:00</DateLastUpdated>
        <Article>
            <PubmedId>10669766</PubmedId>
            <Abstract>The reactivities of two panels of anti-HAV human sera from geographically distinct areas (Chile and Spain) to synthetic peptides from the VP1, VP2 and VP3 hepatitis A virus capsid proteins were examined by an enzyme-linked immunosorbent assay (ELISA) procedure. Two and four branched multiple antigenic peptides (MAPs) and palmitoylated peptides were compared with free synthetic sequences for the detection of IgM anti-HAV antibodies in the two panels of human sera. Our results showed that acute hepatitis A patient sera recognized preferentially homogeneous two branched MAPs and palmitic acid conjugated peptides. The palmitoyl-derived VP3(110-121) peptide and the corresponding dimeric MAP were the most sensitive and appropriate for serological studies of HAV-infected patients by ELISA, sensitivity and specificity being higher than 90% and 95%, respectively. These peptide-based tests open up new avenues in the development of peptide-based immunosorbent assays for the detection of acute HAV disease.</Abstract>
            <ArticleYear>2000</ArticleYear>
            <ArticlePages>23-34</ArticlePages>
            <ArticleTitle>Use of linear and multiple antigenic peptides in the immunodiagnosis of acute hepatitis A virus infection.</ArticleTitle>
            <Authors>
                <Author>
                    <LastName>Gómara</LastName>
                    <ForeName>M J</ForeName>
                </Author>
                <Author>
                    <LastName>Riedemann</LastName>
                    <ForeName>S</ForeName>
                </Author>
                <Author>
                    <LastName>Vega</LastName>
                    <ForeName>I</ForeName>
                </Author>
                <Author>
                    <LastName>Ibarra</LastName>
                    <ForeName>H</ForeName>
                </Author>
                <Author>
                    <LastName>Ercilla</LastName>
                    <ForeName>G</ForeName>
                </Author>
                <Author>
                    <LastName>Haro</LastName>
                    <ForeName>I</ForeName>
                </Author>
            </Authors>
            <Affiliations>Departament de Química de Pèptids i Proteïnes, IIQAB-CSIC, Jordi Girona 18-26, 08034, Barcelona, Spain.</Affiliations>
            <ArticleChemicalList>Antigens, Viral;Capsid Proteins;Epitopes, B-Lymphocyte;Hepatitis A Antibodies;Hepatitis A Antigens;Hepatitis Antibodies;Peptide Fragments;Peptides;Reagent Kits, Diagnostic;VP1 protein, hepatitis A virus;VP3 peptide (110-121), hepatitis A virus;Viral Structural Proteins;Palmitic Acid</ArticleChemicalList>
            <ArticleMeshHeadingsList>Acute Disease; Antigens, Viral(immunology); Capsid(chemical synthesis; immunology); Capsid Proteins; Enzyme-Linked Immunosorbent Assay(methods); Epitopes, B-Lymphocyte(immunology); Hepatitis A(blood; diagnosis; immunology); Hepatitis A Antibodies; Hepatitis A Antigens; Hepatitis Antibodies(blood; immunology); Humans; Immunologic Tests(methods); Palmitic Acid(immunology); Peptide Fragments(chemical synthesis; immunology); Peptides(chemical synthesis; immunology); Reagent Kits, Diagnostic; Reproducibility of Results; Sensitivity and Specificity; Viral Structural Proteins(chemical synthesis; immunology)</ArticleMeshHeadingsList>
            <Journal>
                <Volume>234</Volume>
                <Issue>1-2</Issue>
                <Title>Journal of immunological methods</Title>
                <Issn>1872-7905</Issn>
                <MedlineTa>J Immunol Methods</MedlineTa>
            </Journal>
        </Article>
        <Epitopes>
            <Epitope>
                <EpitopeName>VP1 (11-25)</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>TVSTEQNVPDPQVGI</LinearSequence>
                        <StartingPosition>11</StartingPosition>
                        <EndingPosition>25</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>AAR01152.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>12092</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Figure 1</LocationOfData>
                <EpitopeId>67170</EpitopeId>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <Assays>
                    <BCell>
                        <LocationOfData>Table 2 and figure 3</LocationOfData>
                        <BCellId>18899</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:12549</DiseaseState>
                                <DiseaseStage>Acute/Recent onset</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>12092</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Sera were obtained from patients (30 from Chile, 9 from Spain) that fulfilled the following criteria 1) a clinical illness compatible with acute viral hepatitis, 2) a peak of alanine aminotransferase (ALT) values at least 10 times of normal, 3) negative results for HbsAg, HBc IgM, no antibodies to EBV, CMV or HCV, and 4) positive IgM anti-Hepatitis A virus (HAVAB-M, Abbott Lab, Chicago, IL, USA).</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>39</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>27</NumberOfSubjectsResponded>
                            <ResponseFrequency>69.2</ResponseFrequency>
                            <AssayComments>The assay antigen was a lipidated (palmitic acid) MAP containing two copies of the epitope. .</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>Palm-VP1</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>TVSTEQNVPDPQVGI</LinearSequence>
                                        <StartingPosition>11</StartingPosition>
                                        <EndingPosition>25</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>AAR01152.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>12092</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                            <AntigenContainingObject>
                                <ComplexedMolecule>
                                    <ComplexType>Multi-Antigenic Peptide (MAP, branched)</ComplexType>
                                    <PeptideModifications/>
                                </ComplexedMolecule>
                            </AntigenContainingObject>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Table 2 and figure 3</LocationOfData>
                        <BCellId>18898</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:12549</DiseaseState>
                                <DiseaseStage>Acute/Recent onset</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>12092</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Sera were obtained from patients (30 from Chile, 9 from Spain) that fulfilled the following criteria 1) a clinical illness compatible with acute viral hepatitis, 2) a peak of alanine aminotransferase (ALT) values at least 10 times of normal, 3) negative results for HbsAg, HBc IgM, no antibodies to EBV, CMV or HCV, and 4) positive IgM anti-Hepatitis A virus (HAVAB-M, Abbott Lab, Chicago, IL, USA).</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>39</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>21</NumberOfSubjectsResponded>
                            <ResponseFrequency>53.8</ResponseFrequency>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>VP1 (11-25)</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>TVSTEQNVPDPQVGI</LinearSequence>
                                        <StartingPosition>11</StartingPosition>
                                        <EndingPosition>25</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>AAR01152.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>12092</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Table 2 and figure 3</LocationOfData>
                        <BCellId>18910</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:12549</DiseaseState>
                                <DiseaseStage>Acute/Recent onset</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>12092</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Sera were obtained from patients (30 from Chile, 9 from Spain) that fulfilled the following criteria 1) a clinical illness compatible with acute viral hepatitis, 2) a peak of alanine aminotransferase (ALT) values at least 10 times of normal, 3) negative results for HbsAg, HBc IgM, no antibodies to EBV, CMV or HCV, and 4) positive IgM anti-Hepatitis A virus (HAVAB-M, Abbott Lab, Chicago, IL, USA).</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>39</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>25</NumberOfSubjectsResponded>
                            <ResponseFrequency>64.1</ResponseFrequency>
                            <AssayComments>The assay antigen was a MAP containing 4 copies of the epitope.The carrier consisted of MAP4.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgM</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>MAP4-VP1</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>TVSTEQNVPDPQVGI</LinearSequence>
                                        <StartingPosition>11</StartingPosition>
                                        <EndingPosition>25</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>AAR01152.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>12092</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                            <AntigenContainingObject>
                                <ComplexedMolecule>
                                    <ComplexType>Multi-Antigenic Peptide (MAP, branched)</ComplexType>
                                    <PeptideModifications/>
                                </ComplexedMolecule>
                            </AntigenContainingObject>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>VP2 (96-107)</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>GLLRYHTYARFG</LinearSequence>
                        <StartingPosition>96</StartingPosition>
                        <EndingPosition>107</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>NP_740550.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>12092</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Figure 1</LocationOfData>
                <EpitopeId>21026</EpitopeId>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <Assays>
                    <BCell>
                        <LocationOfData>Table 2 and figure 3</LocationOfData>
                        <BCellId>18901</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:12549</DiseaseState>
                                <DiseaseStage>Acute/Recent onset</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>12092</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Sera were obtained from patients (30 from Chile, 9 from Spain) that fulfilled the following criteria 1) a clinical illness compatible with acute viral hepatitis, 2) a peak of alanine aminotransferase (ALT) values at least 10 times of normal, 3) negative results for HbsAg, HBc IgM, no antibodies to EBV, CMV or HCV, and 4) positive IgM anti-Hepatitis A virus (HAVAB-M, Abbott Lab, Chicago, IL, USA).</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>39</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>26</NumberOfSubjectsResponded>
                            <ResponseFrequency>66.7</ResponseFrequency>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>VP2 (96-107)</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>GLLRYHTYARFG</LinearSequence>
                                        <StartingPosition>96</StartingPosition>
                                        <EndingPosition>107</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_740550.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>12092</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Table 2 and figure 3</LocationOfData>
                        <BCellId>18911</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:12549</DiseaseState>
                                <DiseaseStage>Acute/Recent onset</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>12092</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Sera were obtained from patients (30 from Chile, 9 from Spain) that fulfilled the following criteria 1) a clinical illness compatible with acute viral hepatitis, 2) a peak of alanine aminotransferase (ALT) values at least 10 times of normal, 3) negative results for HbsAg, HBc IgM, no antibodies to EBV, CMV or HCV, and 4) positive IgM anti-Hepatitis A virus (HAVAB-M, Abbott Lab, Chicago, IL, USA).</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>39</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>28</NumberOfSubjectsResponded>
                            <ResponseFrequency>71.8</ResponseFrequency>
                            <AssayComments>The assay antigen was a MAP containing 4 copies of the epitope.The carrier consisted of MAP4.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgM</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>MAP4-VP2</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>GLLRYHTYARFG</LinearSequence>
                                        <StartingPosition>96</StartingPosition>
                                        <EndingPosition>107</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_740550.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>12092</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                            <AntigenContainingObject>
                                <ComplexedMolecule>
                                    <ComplexType>Multi-Antigenic Peptide (MAP, branched)</ComplexType>
                                    <PeptideModifications/>
                                </ComplexedMolecule>
                            </AntigenContainingObject>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>VP3 (110-121)</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>FWRGDLVFDFQV</LinearSequence>
                        <StartingPosition>110</StartingPosition>
                        <EndingPosition>121</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>AAR01187.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>12092</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Figure1</LocationOfData>
                <EpitopeId>18363</EpitopeId>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <Assays>
                    <BCell>
                        <LocationOfData>Table 2 and figure 3</LocationOfData>
                        <BCellId>18902</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:12549</DiseaseState>
                                <DiseaseStage>Acute/Recent onset</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>12092</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Sera were obtained from patients (30 from Chile, 9 from Spain) that fulfilled the following criteria 1) a clinical illness compatible with acute viral hepatitis, 2) a peak of alanine aminotransferase (ALT) values at least 10 times of normal, 3) negative results for HbsAg, HBc IgM, no antibodies to EBV, CMV or HCV, and 4) positive IgM anti-Hepatitis A virus (HAVAB-M, Abbott Lab, Chicago, IL, USA).</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>39</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>15</NumberOfSubjectsResponded>
                            <ResponseFrequency>38.5</ResponseFrequency>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>VP3 (110-121)</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>FWRGDLVFDFQV</LinearSequence>
                                        <StartingPosition>110</StartingPosition>
                                        <EndingPosition>121</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>AAR01187.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>12092</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <BCellId>18916</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:12549</DiseaseState>
                                <DiseaseStage>Acute/Recent onset</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>12092</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <ImmunizationComments>A highly reactive anti-HAV serum was used for the inhibition (ELISA) assay; the epitope or MAPs containing 2 or 4 copies of the epitope were used as assay antigens.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>311</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Inhibition of antibody binding to the MAP antigens (MAP2- or MAP4-VP3) was achieved at 50 ug/ml, whereas it took 4 times as much (200 ug/ml) to inhibit the peptide (VP3) antigen.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgM</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>VP3 (110-121)</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>FWRGDLVFDFQV</LinearSequence>
                                        <StartingPosition>110</StartingPosition>
                                        <EndingPosition>121</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>AAR01187.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>12092</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Table 2 and figure 3</LocationOfData>
                        <BCellId>18906</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:12549</DiseaseState>
                                <DiseaseStage>Acute/Recent onset</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>12092</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Sera were obtained from patients (30 from Chile, 9 from Spain) that fulfilled the following criteria 1) a clinical illness compatible with acute viral hepatitis, 2) a peak of alanine aminotransferase (ALT) values at least 10 times of normal, 3) negative results for HbsAg, HBc IgM, no antibodies to EBV, CMV or HCV, and 4) positive IgM anti-Hepatitis A virus (HAVAB-M, Abbott Lab, Chicago, IL, USA).</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>39</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>30</NumberOfSubjectsResponded>
                            <ResponseFrequency>76.9</ResponseFrequency>
                            <AssayComments>The assay antigen was lipidated (palmitic acid). .</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>Palm-VP3</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>FWRGDLVFDFQV</LinearSequence>
                                        <StartingPosition>110</StartingPosition>
                                        <EndingPosition>121</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>AAR01187.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>12092</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                            <AntigenContainingObject>
                                <ComplexedMolecule>
                                    <ComplexType>Multi-Antigenic Peptide (MAP, branched)</ComplexType>
                                    <PeptideModifications/>
                                </ComplexedMolecule>
                            </AntigenContainingObject>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Table 2 and figure 3</LocationOfData>
                        <BCellId>18913</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:12549</DiseaseState>
                                <DiseaseStage>Acute/Recent onset</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>12092</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Sera were obtained from patients (30 from Chile, 9 from Spain) that fulfilled the following criteria 1) a clinical illness compatible with acute viral hepatitis, 2) a peak of alanine aminotransferase (ALT) values at least 10 times of normal, 3) negative results for HbsAg, HBc IgM, no antibodies to EBV, CMV or HCV, and 4) positive IgM anti-Hepatitis A virus (HAVAB-M, Abbott Lab, Chicago, IL, USA).</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>39</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>22</NumberOfSubjectsResponded>
                            <ResponseFrequency>56.4</ResponseFrequency>
                            <AssayComments>The assay antigen was a MAP containing 4 copies of the epitope.The carrier consisted of MAP4.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgM</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>MAP4-VP3</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>FWRGDLVFDFQV</LinearSequence>
                                        <StartingPosition>110</StartingPosition>
                                        <EndingPosition>121</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>AAR01187.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>12092</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                            <AntigenContainingObject>
                                <ComplexedMolecule>
                                    <ComplexType>Multi-Antigenic Peptide (MAP, branched)</ComplexType>
                                    <PeptideModifications/>
                                </ComplexedMolecule>
                            </AntigenContainingObject>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Table 2 and figure 3</LocationOfData>
                        <BCellId>18915</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:12549</DiseaseState>
                                <DiseaseStage>Acute/Recent onset</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>12092</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Sera were obtained from patients (30 from Chile, 9 from Spain) that fulfilled the following criteria 1) a clinical illness compatible with acute viral hepatitis, 2) a peak of alanine aminotransferase (ALT) values at least 10 times of normal, 3) negative results for HbsAg, HBc IgM, no antibodies to EBV, CMV or HCV, and 4) positive IgM anti-Hepatitis A virus (HAVAB-M, Abbott Lab, Chicago, IL, USA).</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>39</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>33</NumberOfSubjectsResponded>
                            <ResponseFrequency>84.6</ResponseFrequency>
                            <AssayComments>The assay antigen was a MAP containing 2 copies of the epitope.The carrier consisted of MAP2.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>MAP2-VP3</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>FWRGDLVFDFQV</LinearSequence>
                                        <StartingPosition>110</StartingPosition>
                                        <EndingPosition>121</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>AAR01187.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>12092</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                            <AntigenContainingObject>
                                <ComplexedMolecule>
                                    <ComplexType>Multi-Antigenic Peptide (MAP, branched)</ComplexType>
                                    <PeptideModifications/>
                                </ComplexedMolecule>
                            </AntigenContainingObject>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>VP3 (102-121)</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>ASICQMFCFWRGDLVFDFQV</LinearSequence>
                        <StartingPosition>102</StartingPosition>
                        <EndingPosition>121</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>AAR01187.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>12092</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Figure 1</LocationOfData>
                <EpitopeId>4467</EpitopeId>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <Assays>
                    <BCell>
                        <LocationOfData>Table 2 and figure 3</LocationOfData>
                        <BCellId>18907</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:12549</DiseaseState>
                                <DiseaseStage>Acute/Recent onset</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>12092</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Sera were obtained from patients (30 from Chile, 9 from Spain) that fulfilled the following criteria 1) a clinical illness compatible with acute viral hepatitis, 2) a peak of alanine aminotransferase (ALT) values at least 10 times of normal, 3) negative results for HbsAg, HBc IgM, no antibodies to EBV, CMV or HCV, and 4) positive IgM anti-Hepatitis A virus (HAVAB-M, Abbott Lab, Chicago, IL, USA).</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>39</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>32</NumberOfSubjectsResponded>
                            <ResponseFrequency>82.1</ResponseFrequency>
                            <AssayComments>The assay antigen was lipidated (palmitic acid). .</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>Palm-VP3</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>ASICQMFCFWRGDLVFDFQV</LinearSequence>
                                        <StartingPosition>102</StartingPosition>
                                        <EndingPosition>121</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>AAR01187.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>12092</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                            <AntigenContainingObject>
                                <ComplexedMolecule>
                                    <ComplexType>Multi-Antigenic Peptide (MAP, branched)</ComplexType>
                                    <PeptideModifications/>
                                </ComplexedMolecule>
                            </AntigenContainingObject>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Table 2 and figure 3</LocationOfData>
                        <BCellId>18903</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:12549</DiseaseState>
                                <DiseaseStage>Acute/Recent onset</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>12092</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Sera were obtained from patients (30 from Chile, 9 from Spain) that fulfilled the following criteria 1) a clinical illness compatible with acute viral hepatitis, 2) a peak of alanine aminotransferase (ALT) values at least 10 times of normal, 3) negative results for HbsAg, HBc IgM, no antibodies to EBV, CMV or HCV, and 4) positive IgM anti-Hepatitis A virus (HAVAB-M, Abbott Lab, Chicago, IL, USA).</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>39</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>28</NumberOfSubjectsResponded>
                            <ResponseFrequency>71.8</ResponseFrequency>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>VP3 (102-121)</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>ASICQMFCFWRGDLVFDFQV</LinearSequence>
                                        <StartingPosition>102</StartingPosition>
                                        <EndingPosition>121</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>AAR01187.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>12092</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
        </Epitopes>
    </Reference>
</References>

